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Abstract
We retrospectively evaluated the effect of locoregional treatment (LRT) on overall survival (OS) in 300 meta-
static at diagnosis (M1) prostate cancer patients. LRT was associated in univariate and multivariate analysis
with longer OS, which remained signiﬁcant for radiotherapy but not for transurethral prostatectomy. These
data support further prospective evaluation of the beneﬁt of local control in this patient population.
Background: The optimal management of the primary tumor in metastatic at diagnosis (M1) prostate cancer (PCa)
patients is not yet established. We retrospectively evaluated the effect of locoregional treatment (LRT) on overall survival
(OS) hypothesizing that this could improve outcome through better local disease control and the induction of an anti-
tumor immune response (abscopal effect). Patients and Methods:M1 at diagnosis PCa patients referred to the Prostate
Targeted Therapy Group at the Royal Marsden between June 2003 and December 2013 were identiﬁed. LRT was
deﬁned as either surgery, radiotherapy (RT) or transurethral prostatectomy (TURP) administered to the primary tumor at
any time point from diagnosis to death. KaplaneMeier analyses generated OS data. The association between LRT and
OS was evaluated in univariate (UV) and multivariate (MV) Cox regression models. Results: Overall 300 patients were
identiﬁed; 192 patients (64%) experienced local symptoms at some point during their disease course; 72 patients
received LRT (56.9% TURP, 52.7% RT). None of the patients were treated with prostatectomy. LRT was more frequently
performed in patients with low volume disease (35.4% vs. 16.2%; P < .001), lower prostate-speciﬁc antigen (PSA) level
at diagnosis (median PSA: 75 vs. 184 ng/mL; P ¼ .005) and local symptoms (34.2% vs. 4.8%; P < .001). LRT was
associated in UV and MV analysis with longer OS (62.1 vs. 55.8 months; hazard ratio [HR], 0.74; P ¼ .044), which
remained signiﬁcant for RT (69.4 vs. 55.1 months; HR, 0.54; P ¼ .002) but not for TURP. RT was associated with better
OS independent of disease volume at diagnosis. Conclusion: These data support the conduct of randomized phase III
trials to evaluate the beneﬁt of local control in patients with M1 disease at diagnosis.
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OS and LRT in mPCaIntroduction symptoms in this population, their management, and the treating
The standard management of de novo metastatic prostate cancer
(mPCa) has recently changed to combine docetaxel chemotherapy
with androgen deprivation therapy (ADT) for ﬁt patients.1-3
Deﬁnitive treatment of the local prostate tumor in the form of
surgery or radiotherapy (RT) is not generally contemplated for
asymptomatic patients in the metastatic setting; rather it is usually
reserved for patients with organ-conﬁned or locally advanced
prostate cancer (PCa). The role of locoregional treatment (LRT)
such as surgery, RT, or transurethral prostatectomy (TURP) in
mPCa is mostly used for the palliation of local symptoms such as
hematuria or urinary obstruction, and its effect on overall survival
(OS) remains undeﬁned.
This treatment paradigm has been challenged by a growing
body of evidence on the basis of several retrospective studies4-8
suggesting a potential OS beneﬁt from radical prostatectomy or
RT for patients with mPCa at diagnosis. For several other
malignancies, including colorectal, kidney, and ovarian cancer,
maximal cytoreduction including removal of the primary tumor
has been shown to provide an OS advantage.9-13 In breast cancer,
despite several retrospective series suggesting a similar favorable
effect, a recently published randomized controlled trial failed to
conﬁrm such evidence.14
Besides the more intuitive rationale for treating the primary
tumor, whereby the reduction of the overall tumor burden might
limit the risk of metastatic spread, emerging preclinical evidence
now supports a more aggressive treatment approach for the local
prostate tumor even in the metastatic setting. The “tumor self-
seeding theory” suggests that circulating tumor cells might spread
and metastasize not only from the primary site to distant organs but
also in the opposite direction, reinﬁltrating the site of origin, which
could become a reservoir of tumor cells with metastatic potential.15
Moreover, LRT of the primary tumor could act as an effective
endogenous vaccine through tumor antigen shedding, resulting in
the regression not only of the directly treated local tumor but also of
the distant metastatic sites through “abscopal effects”.16 RT-induced
inﬂammation and tumor necrosis is also postulated to cause the
acute release of multiple tumor-associated antigens, which in turn
elicit a speciﬁc CD8þ T-cell mediated antitumor immunological
effect.16 This secondary immunological response could potentially
convert RT into a potent systemic treatment with unexplored
clinical beneﬁts, which go beyond mere local control or symptom
palliation. Primary tumor-derived exosomes and cytokines have also
been postulated to contribute to the creation of a receptive micro-
environment (“pre-metastatic niche”) for the subsequent develop-
ment of metastatic sites in speciﬁc organs. It has been suggested that
the untreated primary disease continues to affect the growth of the
metastatic disease in an endocrine manner.17
Several ongoing large prospective phase II and III trials are
investigating whether LRT should be recommended in mPCa
patients (NCT01751438, NCT02138721, NCT01957436,
NCT00268476). In the present study we aimed to determine the
survival of patients who underwent LRT administered at any time
point along the course of the disease in a retrospective study to
evaluate a population of patients diagnosed with mPCa at presen-
tation. Secondarily, we described the type and the incidence of localnical Genitourinary Cancer Month 2017physician’s rationale for prescribing LRT.
Patients and Methods
Study Population and Data Collection
Prostate cancer patients with metastatic disease at diagnosis
referred to the Prostate Targeted Therapy Group at the Royal
Marsden NHS Foundation Trust between June 2003 and
December 2013 were selected. The time of data cutoff was
January 16, 2016. Clinical patient data were collected from the
Electronic Patients Record. Variables including age, diagnostic
Gleason score, Eastern Cooperative Oncology Group (ECOG)
performance status (PS) at diagnosis or ﬁrst referral, post
castration-resistant PCa (CRPC) lines of standard therapies
received, prostate-speciﬁc antigen (PSA) level at diagnosis, meta-
static sites, and volume of disease at diagnosis or ﬁrst referral and
at the time of LRT, were retrospectively recorded. Information on
local symptoms (pelvic pain, hematuria, urinary frequency, uri-
nary retention, hydronephrosis), intervention (medications,
TURP, surgery, RT, cystoscopy, suprapubic catheterization,
ureteric stenting, hospitalization, and catheterization) at diagnosis
and/or at any time point along the course of the disease; the
physician decision rationale and treatment intent for LRT were
also collected.
Locoregional treatment was deﬁned as the receipt of treatment
to the primary tumor consisting of either surgery (radical prosta-
tectomy), RT (administered at any dose and fractionation), or
TURP at any time point along the disease course from diagnosis
to death. The volume of disease was classiﬁed according to Che-
moHormonal Therapy Versus Androgen Ablation Randomized
Trial for Extensive Disease (CHAARTED) criteria1 into high
(presence of visceral metastases or  4 bone lesions of which at least
1 beyond the vertebral bodies and pelvis) or low volume (< 4 bone
lesions without visceral metastases). The intent of RT was catego-
rized as either palliative (palliation of local symptoms) or radical
(deﬁnitive local RT only or in combination with external beam
radiation therapy [EBRT] directed to the metastatic sites in the
context of oligometastatic or oligorecurrent disease).18
Statistical Analysis
A descriptive analysis of clinical variables was performed. Cate-
gorical variables were presented as proportions (%) and continuous
variables were presented by the median values with interquartile
range. Differences in baseline variables between groups of those who
received LRT and those who did not receive LRT were evaluated
using c2 (categorical values) and Student t tests (continuous
variables).
Median survival values for each of the groups were calculated using
KaplaneMeier analyses. The association of LRT with survival was
evaluated in univariable and multivariable Cox regression models.
Variables in the multivariable model included LRT, age, PSA (log-
transformed), Gleason score, tumor volume, and the presence of
symptoms. Cox regression models were estimated for LRT (RT and
surgery) and for RT and surgery and LRT separately. Only
P values < .05 were considered statistically signiﬁcant. No correction
for multiple testing was performed.
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Patient Characteristics and Local Symptoms
Overall 300 PCa patients with metastatic disease at diagnosis
were identiﬁed. Patient characteristics at diagnosis or ﬁrst referral are
summarized in Table 1. Most patients (95.6%) presented with good
baseline ECOG PS (0 or 1) and received a median of 3 lines of
treatment for metastatic CRPC. In total 192 patients (64%) expe-
rienced local symptoms at some point during their disease course
with 99 patients (33%) having these at diagnosis and 148 patients
(49.3%) developing symptoms later on during the course of the
disease. Clinical data on local symptoms during the course of the
disease were not available in 4 of the 192 symptomatic patients.
Follow-up of these local symptoms in the 99 patients who were
symptomatic at diagnosis indicated that 42 of these patients (42 of
99; 42.4%) did not report any further local symptoms during the
course of the disease of whom only 20 had received a speciﬁc
intervention for their local symptoms. Fifty-three patients (53 of 99;
53.5%) continued to experience local symptoms with 19 reporting
the same (19 of 53; 35.8%), 32 worsening (32 of 53; 60.3%), and 2
improving local symptoms (2 of 53; 3.7%). Follow-up data on these
local symptoms were not available for 4 patients. Of the 99 patients
who presented with local symptoms at diagnosis, 44 patients
(44.4%) received medical intervention to manage their local
symptoms whereas 55 patients (55.5%) did not. In the 44 patients
who received medical intervention, local symptoms resolved duringTable 1 Patient Characteristics
All Patients LRT No LRT
Median Age
(Range), y
63 (57.7-68.5) 62.2 (56.9-66.5) 63.1 (57.8-68.6)
ECOG PS, n (%)
0-1 287 (95.7) 64 (92.8) 217 (96.4)
2 13 (4.3) 5 (7.2) 8 (3.6)
Mean PSA (Range),
(ng/mL)
150 (55-500) 75 (35-381) 184 (65.3-533.5)
Gleason Score,
n (%)
8 164 (54.7) 44 (63.8) 116 (51.6)
<8 66 (22) 16 (23.2) 49 (21.8)
Unknown 70 (23.3) 9 (13) 60 (26.7)
Metastatic Sites,
n (%)
Bone 265 (88.3) 54 (78.3) 207 (92)
Lymph nodes 83 (27.7) 23 (33.3) 56 (24.9)
Visceral 15 (5) 4 (5.8) 11 (4.9)
Tumor Burden
(CHAARTED
Criteria), n (%)
High 181 (60.3) 29 (42) 150 (66.7)
Low 117 (39) 40 (58) 73 (32.4)
Mean Post-CRPC
Lines of Treatment
(Range), n
3 (2-3) 3 (2-3) 3 (2-3)
Abbreviations: CHAARTED ¼ ChemoHormonal Therapy Versus Androgen Ablation Randomized
Trial for Extensive Disease; CRPC ¼ castration-resistant prostate cancer; ECOG ¼ Eastern
Cooperative Oncology Group; LRT ¼ locoregional treatment; PS ¼ performance status; PSA ¼
prostate-speciﬁc antigen.the course of the disease in 19 (19 of 44; 43.1%), improved in
3 (3 of 44; 6.8%), and persisted or worsened in 18 patients (18 of
44; 40.9%).
Urinary frequency was the most commonly reported symptom at
diagnosis (20%), followed by urinary retention (7.3%), hematuria
(4.3%), pelvic pain (4%), and hydronephrosis (2%; Table 2).
During the course of the disease, urinary frequency remained the
most frequently reported local symptom (37.7%) followed by pelvic
pain (12.7%), urinary retention (12%), hematuria (11%), and
hydronephrosis (8.7%).
Locoregional Treatment
Overall 72 patients (24%) received LRT to the primary tumor
(Table 3);18 (25%) received this at diagnosis and 54 (75%) later
during the course of the disease. Of these, most were symptomatic
with only 13 (18%) being free of local symptoms from the primary
tumor at the time LRT was performed. For those who received LRT
during the course of the disease, median time from diagnosis to
LRT was 41.6 (range, 6.9-170.1) months.
The most common form of LRT was TURP in 41 patients
(56.9%) followed by RT in 38 patients (52.7%); 8 patients (11.6%)
underwent TURP as well as RT; 1 patient (1.4%) had focal surgical
intervention (laser prostatectomy) but none of the patients received
radical prostatectomy.
All patients treated with TURP reported local symptoms at the
time of treatment; 15 patients (38.5%) had a TURP performed at
diagnosis and 26 patients (63.4%) later during the course of treat-
ment. For those treated during the course of the disease, median time
from diagnosis to TURP was 38.9 months (range, 8-119 months).
Of those treated with RT, 63.2% were symptomatic from the
local tumor at the time of local RT; 5 patients (13.2%) received RT
at diagnosis and 33 patients (86.8%) later during the course of the
disease. In those treated during the course of the disease, median
time from diagnosis to RT was 46.7 (range, 6.9-170.1) months.
Among these 33 patients treated with local RT along the disease
course, 24 patients were symptomatic from the local tumor at the
time of administration of RT. After local irradiation, local symp-
toms improved or resolved in 12 patients (12 of 24; 50%) but
persisted or worsened in the other 12 patients (12 of 24; 50%). Of
the 156 patients with local symptoms but not treated with RT,
27 patients (17.3%) required multiple treatments to control local
progression.
Radiotherapy with radical intent was administered to the primary
tumor to 16 patients (42.1%) with oligometastatic or oligorecurrent
disease18 of whom 8 patients were treated with synchronous EBRT
to additional bone or nodal metastatic lesions. Twenty-one patients
(55.3%) received RT with the intent to palliate local symptoms or
improve the local control of the disease. Data on 1 of these patients
were missing. Twenty-six patients (76.5%) received at least 30 Gy,
and 6 patients (15.8%) were treated with doses of 60 Gy or higher;
the dose was unknown in 4 patients (10.5%) and fractionation was
inconsistently reported.
Locoregional treatment was more frequently performed in
patients with low-volume metastatic disease (35.4% vs. 16.2%; P <
.001), lower PSA level at diagnosis (median PSA: 75 vs. 184 ng/mL;
P ¼ .005), and with local symptoms (34.2% vs. 4.8%; P < .001).
No signiﬁcant association was found with age (median age: 63.1 vs.Clinical Genitourinary Cancer Month 2017 - 3
Table 2 Local Symptoms
All Patients (n [ 294) LRT (n [ 69) No LRT (n [ 225)
At Diagnosis During Disease At Diagnosis During Disease At Diagnosis During Disease
At Least 1 Symptom 96 (32) 147 (49.3) 32 (46.4) 56 (81.2) 60 (26.7) 91 (40.4)
Pelvic Pain 12 (4) 38 (12.7) 4 (5.8) 14 (20.3) 6 (2.7) 23 (10.2)
Hematuria 13 (4.3) 33 (11) 4 (5.8) 18 (26.1) 9 (4) 14 (6.2)
Urinary Frequency 60 (20) 113 (37.7) 17 (24.6) 42 (60.9) 41 (18.2) 71 (31.6)
Urinary Retention 22 (7.3) 36 (12) 11 (15.9) 18 (26.1) 9 (4) 18 (8)
Hydronephrosis 6 (2) 26 (8.7) 3 (4.3) 18 (26.1) 3 (1.3) 8 (3.6)
Data are presented as n (%). Information on symptoms was missing for 6 patients (2%).
Abbreviation: LRT ¼ locoregional treatment.
OS and LRT in mPCa
4 - Cli62.2 years; P ¼ .409) or Gleason Score  8 (24.6% vs. 27.5%;
P ¼ .657). The pattern of metastatic spread was not clearly asso-
ciated with LRT. Although there was a nonsigniﬁcant trend toward
patients with lymph node-only disease receiving LRT in higher
proportion (37% vs. 21.5%; P ¼ .068), no differences were
observed in patients with visceral (22.7% vs. 26.7%; P ¼ .725) or
bone-only (28.7% vs. 20.5%; P ¼ .125) metastases.
Survival
Median follow-up was 54.6 (range, 11.9-227.8) months, with
266 (88.7%) deaths. Median OS for the whole cohort was
57.9 months (95% conﬁdence interval, 51.9-63.9; Figure 1A). In
univariate analysis, LRT was associated with better OS (62.1 vs.
55.8 months; hazard ratio [HR], 0.74; P ¼ .044). LRT was also
associated with improved survival in a multivariable model
including age, Gleason Score, PSA, volume of disease (low vs. high)
at diagnosis and presence of symptoms as covariates (Table 4, sec-
tion A). We then evaluated whether the type of LRT (RT or TURP/
surgery) would have an equivalent effect on OS. In univariate
analysis, TURP/surgery was associated with a nonsigniﬁcant
decrease in OS (54.3 vs. 58.8 months; HR, 1.23; P ¼ .239)
(Figure 1B), whereas patients who received local RT appeared to
have a signiﬁcant OS advantage (69.4 vs. 55.1 months; HR, 0.54;
P ¼ .002; Figure 1C), which was maintained in the multivariable
Cox regression model (Table 4, section B). There was no signiﬁcant
interaction between RT treatment administration and diseaseTable 3 Locoregional Treatment
At Diagnosis
(n [ 18)
During Course of the
Disease (n [ 54)
TURP Only 13 (72.2%) 20 (37%)
Surgery Only 0 0
Radiotherapy Only 3 (16.7%) 28 (51.9%)
TURP and Surgery 0 1 (1.9%)
TURP and
Radiotherapy
2 (11.1%) 5 (9.3%)
Radiotherapy and
Surgery
0 0
Data are presented as n (%). Three patients had locoregional treatment at diagnosis and during
the course of the disease: 2 patients had transurethral prostatectomy (TURP) at diagnosis and
TURP during the course of the disease, and 1 patient had TURP at diagnosis and radiotherapy
during the course of the disease.
nical Genitourinary Cancer Month 2017volume evaluated at diagnosis or ﬁrst referral (CHAARTED
criteria)1 (P ¼ .958). Higher RT doses were associated with
increased OS independently of the volume of disease assessed at
diagnosis or ﬁrst referral (P < .001).
Discussion
The past decade has seen a major change in therapeutic options
for mPCa patients with several novel and effective drugs receiving
regulatory approval, resulting in signiﬁcant OS improvements. As a
consequence, in our experience, an increasing number of patients
are developing symptoms secondary to local progression of
untreated primary disease. Furthermore, although the local tumor
tends to respond well to initial ADT, the adaptive resistance
mechanisms induced by subsequent lines of hormonal or chemo-
therapy treatment impair the chances of achieving adequate local
control. Small increases in size of the local prostate tumor frequently
result in urinary outﬂow obstruction and the invasion of adjacent
organs that might manifest clinically with macroscopic hematuria,
tenesmus, or hydronephrosis. In our study, more than a half of de
novo mPCa patients had locally symptomatic disease at some point
between diagnosis and death. The appropriate management of these
local PCa complications remains challenging. Furthermore, thera-
peutic interventions might themselves be, in some cases, the cause
of long-term side effects, such as erectile dysfunction, urinary in-
continence, intestinal symptoms, and urinary tract infections.19,20
In our study, a signiﬁcant proportion of the patients who pre-
sented with local symptoms at diagnosis (18 of 44; 40.9%) reported
persistent or worsening local symptoms despite local interventions.
Nearly 1 in 5 M1 at diagnosis patients with local symptoms who did
not receive deﬁnitive treatment to the primary tumor in the form of
radical surgery or RT required multiple local interventions. This
suggests that not treating the primary might not only have impli-
cations to patient morbidity and longevity but also health eco-
nomics. However, RT treatment was efﬁcacious in improving the
local symptoms in only half of the treated patients, suggesting that
this local intervention might have been administered too late in the
disease course. The timing of administration of LRT should not
necessarily coincide with the development of local symptoms but
probably at the ﬁrst evidence of radiological progression.
A recent study published in the New England Journal of Medicine
analyzed patient-reported outcomes on the basis of questionnaires in
patients with localized PCa treated with radical prostatectomy, RT,
or active surveillance. Sexual dysfunction and urinary incontinence
Figure 1 (A) Locoregional Treatment (LRT) and Survival (Transurethral Prostatectomy [TURP] D Radiotherapy [RT]). (B) LRT and
Survival (TURP Only). (C) LRT and Survival (RT Only)
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Table 4 Multivariable Survival Analysis
HR (95% CI) P
(A) LRT Including Radiotherapy
as Well as TURP
LRT 0.68 (0.48-0.96) .030
Age 1 (0.98-1.02) .766
PSA at Dxa 0.69 (0.55-0.86) .001
Gleason scoreb 1.23 (0.93-1.76) .132
Volume of metastasesc 1.89 (1.39-2.58) <.001
Symptoms at diagnosis 1.04 (0.97-1.11) .303
(B) LRT When Only Radiotherapy
is Considered
LRT 0.53 (0.33-0.85) .008
Age 1 (0.97-1.02) .644
PSA at Dxa 0.7 (0.56-0.87) .002
Gleason scoreb 1.29 (0.94-1.77) .120
Volume of metastasesc 1.8 (1.32-2.45) <.001
Symptoms at diagnosis 1.03 (0.96-1.1) .406
Abbreviations: CHAARTED ¼ ChemoHormonal Therapy Versus Androgen Ablation Randomized
Trial for Extensive Disease; Dx ¼ diagnosis; HR ¼ hazard ratio; LRT ¼ locoregional treatment;
PSA ¼ prostate-speciﬁc antigen; TURP ¼ transurethral prostatectomy.
aProstate-speciﬁc antigen at diagnosis was log-transformed.
bGleason score:  8 versus < 8.
cVolume of metastatic disease: high versus low as per CHAARTED criteria.
OS and LRT in mPCa
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treated with radical prostatectomy whereas RT more often induced
changes in bowel habits especially in the long term.21 The appro-
priate identiﬁcation and timely management of patients with locally
advanced disease who are most likely to develop clinically relevant
local symptoms is therefore key to prevent patient morbidity.
This retrospective analysis suggests the possibility of an OS
beneﬁt from LRT in patients who present with mPCa at diagnosis.
This hypothesis has already been proposed by other retrospective
case series from different centers, with similar positive results.4-8
Current guidelines for kidney, ovarian, and colorectal cancer
recommend, whenever technically and clinically feasible, the sur-
gical removal of the primary tumor and the metastatic sites.9-13
Here we explored the effect on OS of different local treatments
analyzing RT and TURP as separate single interventions. As already
mentioned, the primary tumor releases in the circulation tumor
cytokines that might have a role in stimulating tumor growth at the
metastatic sites.15 This implies that any intervention to the local
disease might favorably or unfavorably alter this mechanism and
ultimately affect OS. We suggest the hypothesis that the adminis-
tration of RT to the local tumor might improve OS through not
only the suppression of the aforementioned paracrine cytokines but
also the dissemination of tumor-derived neoantigens triggering an
antitumoral immune response (abscopal effect). On the contrary,
the effect of TURP is more unpredictable with mechanical trauma
disrupting the anatomic barriers surrounding the tumor and
favoring not only the circulation of tumor-derived cytokines and
circulating tumor cells but also tumor neoantigens with consequent
antitumor immune responses.16,17 The effect of TURP on OS
might therefore be different depending on which one of these two
processes predominates. Nondeﬁnitive LRT such as TURP mightnical Genitourinary Cancer Month 2017fail to fully abrogate the release of tumor-derived paracrine factors
but still promote the intravascular dissemination of circulating tu-
mor cells.22 In fact, PCa cells can be detected in the circulation
during the perioperative period in patients who undergo TURP and
other studies have suggested an association of this procedure with
disease progression.22-24
In our study, although local treatment (LRT) overall conferred a
survival advantage (62.1 vs. 55.8 months; HR, 0.74; P ¼ .044),
this was almost entirely restricted to patients receiving RT (69.4 vs.
55.1 months; HR, 0.54; P ¼ .002) as opposed to those who
received TURP (54.3 vs. 58.8 months; HR, 1.23; P ¼ .239). The
survival beneﬁt from local RT appeared to be independent of other
known prognostic variables (age, Gleason Score, PSA, volume of
disease, and presence of symptoms) included in multivariable Cox
regression models. Importantly, the survival beneﬁt was indepen-
dent of the volume of bone metastases, suggesting that patients with
a low as well as a high burden of metastases could potentially beneﬁt
from local RT. These results, although limited by the small number
of patients and its retrospective nature, might indicate that the
overall biological effect of TURP on OS is negligible whereas RT
might instead have a favorable effect on OS. The different effect on
OS between these 2 main local treatment modalities (RT or TURP)
might be, in part, explained by the different rationale for treatment
indication. Although TURP was generally carried out to resolve
urinary symptoms such as urinary obstruction and/or urinary fre-
quency, the rationale for administering RT in nearly half of the
patients was primarily not to palliate local symptoms but rather to
improve local control and prevent the subsequent development of
local symptoms.
We acknowledge that our study has a number of limitations
including its retrospective nature and our population heteroge-
neity. Relatively few patients received local treatment, which is
consistent with current clinical practice, because local treatment in
asymptomatic metastatic patients is not the current standard. With
this, as with other similar retrospective studies published to date,
treatment selection bias (ie, the selection of patients with better
baseline prognostic features for local treatment at baseline) might
signiﬁcantly alter the interpretation of results. In our study,
however, RT to the primary tumor was associated with signiﬁ-
cantly increased OS independently of other important baseline
prognostic factors such as the volume of metastatic disease,
Gleason score, or PSA level. Furthermore, the role of an “abscopal
effect,” suggested as a possible biological mechanism to support
the role of LRT in advanced PCa, cannot be supported in our
series because of the different timing of local therapy in our pa-
tients. The fact that not all patients had local treatment at baseline
might have also led to the selection of those with favorable re-
sponses for local treatment along the course of the disease. Other
studies supporting the role of local therapy in advanced PCa come
from large databases that, unfortunately, do not contain most of
the clinical parameters that were evaluated in our study. This is
one of the ﬁrst studies that takes into account the clinical het-
erogeneity of patients treated with local therapy, the very impor-
tant methodological limitations to conducting similar analyses,
therefore supporting the notion that well conducted, randomized
prospective clinical trials are needed to correctly answer this very
important clinical question.
Diletta Bianchini et alConclusion
Although this was a retrospective study limited by a risk of
selection bias with the possibility of overestimating the OS effect of
local radiation, these data support the rationale for conducting large
randomized phase III trials to determine whether local treatment
improves outcome for metastatic at diagnosis PCa patients. More-
over, our data make clear that not treating local disease in mPCa
patients at diagnosis results in signiﬁcant local disease morbidities
during their lifetime with these patients commonly requiring
invasive interventions with signiﬁcant health economic implications
particularly as patients with mPCa live longer with better systemic
therapies.
Clinical Practice Points
 Local symptoms in de novo mPCa patients are common and
often require multiple invasive interventions with signiﬁcant
effects in terms of morbidity and health economics.
 The deﬁnitive treatment of the primary tumor might favorably
affect outcome and prevent local symptoms.
 Large randomized prospective clinical trials to investigate the OS
beneﬁt of RT to the primary tumor in de novo mPCa patients
such as Systemic Therapy in Advancing or Metastatic Prostate
Cancer: Evaluation of Drug Efﬁcacy (STAMPEDE) are ongoing
and results are eagerly awaited.Acknowledgments
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